http://austinpublishinggroup.com/nuclear-medicine-radiotherapy/
Prostate cancer at stage IV spreads to bone frequently, which
occurs in up to 90%. Bone metastasis is a substantial source of morbidity since
it is related to bone pain and skeletal-related events. 223Ra selectively
targets bone metastases with alpha particle. 223Ra was approved for the
treatment of metastatic castration-resistent prostate cancer patients (CRPC). 223Ra
also releases gamma rays accompanying alpha or beta rays. However, the
therapeutic effect and its radiation dose assessment have not yet been
adequately studied. The side effects and therapeutic effects of 223Ra radiation
therapy by using radiation dosimetry for patients with castration - resistant
prostate cancer needs to be evaluated.
Firstly we performed the investigation of phantom study using
four types of collimators including low-energy general purpose, extendent low
energy general purpose, middle energy general purpose and high energy general
purpose type (Figure 1). We observed that middle energy general purpose image
was more efficient than a dedicated alpha detector which showed remarkably
decreasing counting rates. We therefore constructed procedures and standards
for handling 223Ra in clinical practice.
No comments:
Post a Comment